英文字典中文字典


英文字典中文字典51ZiDian.com



中文字典辞典   英文字典 a   b   c   d   e   f   g   h   i   j   k   l   m   n   o   p   q   r   s   t   u   v   w   x   y   z       







请输入英文单字，中文词皆可：


请选择你想看的字典辞典：
单词字典翻译
Cotgr查看　Cotgr　在百度字典中的解释百度英翻中〔查看〕
Cotgr查看　Cotgr　在Google字典中的解释Google英翻中〔查看〕
Cotgr查看　Cotgr　在Yahoo字典中的解释Yahoo英翻中〔查看〕

安装中文字典英文字典查询工具!


中文字典英文字典工具:
选择颜色:
输入中英文单字

































































英文字典中文字典相关资料:


  • Pharvaris | Late-Stage Biopharma Company Focused on HAE
    Pharvaris is a late-stage biopharma company developing novel, oral bradykinin B2 receptor antagonists to treat and prevent hereditary angioedema attacks
  • Clinical Pipeline - B2 Receptor Antagonism - Pharvaris
    Pharvaris has a platform of novel, potent, and selective B2 receptor antagonist small molecules for the treatment of bradykinin-mediated diseases
  • About Us - Pharvaris
    Pharvaris is a late-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for rare diseases with significant unmet need, initially focused on bradykinin-mediated angioedema and other bradykinin-mediated diseases
  • Deucrictibant Clinical Trials in HAE - Pharvaris
    Pharvaris aims to bring better oral options to meet the needs of people with HAE for on-demand and prophylactic treatment We are developing novel, potent and selective B2-receptor antagonist small molecules for the treatment of HAE
  • Scientific Approach - bradykinin B2 receptor antagonism - Pharvaris
    Antagonism of the bradykinin B2 receptor is a well-tolerated, well-established, clinically proven mechanism of action in HAE 1,2,3 Based on detailed insights into the three-dimensional structure of the B2 receptor, Pharvaris designed a small molecule that fits in the pocket of the B2 receptor, where bradykinin naturally binds 4
  • News Releases - Pharvaris N. V.
    ZUG, Switzerland, June 10, 2025 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykinin-mediated diseases such as hereditary angioedema (HAE) and
  • Disease Focus - HAE Bradykinin-Mediated Diseases - Pharvaris
    Pharvaris aims to bring oral options that meet the needs of people with HAE Deucrictibant is designed to directly target the ultimate event in the HAE cascade, the interaction of bradykinin with the bradykinin B2 receptor, a proven mechanism for the treatment of HAE attacks
  • Pharvaris to Present Deucrictibant Clinical Data and Exploratory . . .
    Pharvaris intends to provide injectable-like efficacy™ and placebo-like tolerability with the convenience of an oral therapy to prevent and treat bradykinin-mediated angioedema attacks With positive data in both Phase 2 prophylaxis and on-demand studies in HAE, Pharvaris is currently evaluating the efficacy and safety of
  • Careers - Pharvaris
    Pharvaris is a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to potentially address all types of bradykinin-mediated angioedema By targeting this clinically proven therapeutic target with novel, oral small molecules, the Pharvaris team is advancing new alternatives to injected therapies for the
  • Contact Us - Pharvaris
    Remember which cookies group you accepted; Essential: Remember your cookie permission setting; Essential: Allow session cookies; Essential: Gather information you input into a contact forms, newsletter and other forms across all pages





中文字典-英文字典  2005-2009